Theranexus SA
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonym… Read more
Theranexus SA (ALTHX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.106x
Based on the latest financial reports, Theranexus SA (ALTHX) has a cash flow conversion efficiency ratio of -0.106x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€199.30K) by net assets (€-1.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Theranexus SA - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Theranexus SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Theranexus SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Theranexus SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nhoa SA
PA:NHOA
|
-0.058x |
|
Jinli Group Holdings Ltd
TW:8429
|
0.001x |
|
IDIS Holdings Co. Ltd
KQ:054800
|
0.019x |
|
WFE Technology Corporation
TWO:6474
|
-0.084x |
|
P.A. Resources Bhd
KLSE:7225
|
-0.020x |
|
LGL Group Inc
NYSE MKT:LGL
|
0.007x |
|
Pan Brothers Tbk
JK:PBRX
|
0.059x |
|
SFOODS
HE:SFOODS
|
0.018x |
Annual Cash Flow Conversion Efficiency for Theranexus SA (2015–2024)
The table below shows the annual cash flow conversion efficiency of Theranexus SA from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-1.66 Million | €-3.37 Million | 2.033x | +171.04% |
| 2023-12-31 | €2.22 Million | €-6.36 Million | -2.862x | -205.08% |
| 2022-12-31 | €5.73 Million | €-5.37 Million | -0.938x | -52.84% |
| 2021-12-31 | €10.18 Million | €-6.25 Million | -0.614x | -11.20% |
| 2020-12-31 | €10.28 Million | €-5.68 Million | -0.552x | -8.61% |
| 2019-12-31 | €9.98 Million | €-5.07 Million | -0.508x | -21.77% |
| 2018-12-31 | €13.41 Million | €-5.60 Million | -0.417x | -312.77% |
| 2017-12-31 | €18.71 Million | €-1.89 Million | -0.101x | +99.38% |
| 2016-12-31 | €89.85K | €-1.47 Million | -16.406x | -3069.12% |
| 2015-12-31 | €1.68 Million | €-867.96K | -0.518x | -- |